These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32860561)

  • 21. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
    Kwan C; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1685-1692. PubMed ID: 33963876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Frouni I; Kwan C; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2139-2144. PubMed ID: 32601846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-parkinsonian effect of the mGlu
    Frouni I; Kwan C; Belliveau S; Hamadjida A; Bédard D; Nuara SG; Gourdon JC; Huot P
    Eur J Pharmacol; 2023 Jan; 939():175429. PubMed ID: 36502960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    Frouni I; Kang W; Bédard D; Belliveau S; Kwan C; Hadj-Youssef S; Bourgeois-Cayer É; Ohlund L; Sleno L; Hamadjida A; Huot P
    Eur J Pharmacol; 2022 Aug; 929():175090. PubMed ID: 35780824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective blockade of the 5-HT
    Kwan C; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2021 Jan; 182():108386. PubMed ID: 33152452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
    Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The highly selective mGlu
    Hamadjida A; Sid-Otmane L; Kwan C; Frouni I; Nafade V; Bédard D; Gagnon D; Wallman MJ; Rouillard C; Parent A; Parent M; Huot P
    Eur J Neurosci; 2020 Jun; 51(12):2412-2422. PubMed ID: 31944461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
    Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
    J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Gandy MN; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    PLoS One; 2012; 7(9):e45587. PubMed ID: 23029119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the mGlu
    Kang W; Frouni I; Kwan C; Bédard D; Nuara SG; Hamadjida A; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Nov; 60(9):6175-6184. PubMed ID: 38936819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined 5-HT
    Kwan C; Frouni I; Nuara SG; Belliveau S; Kang W; Hamadjida A; Bédard D; Beaudry F; Panisset M; Gourdon JC; Huot P
    Neuropharmacology; 2021 Mar; 186():108465. PubMed ID: 33485945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
    Hurley MJ; Patel PH; Jackson MJ; Smith LA; Rose S; Jenner P
    Eur J Neurosci; 2007 Jul; 26(1):171-7. PubMed ID: 17614947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.